Michael Vaslamatzis
Overview
Explore the profile of Michael Vaslamatzis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stathopoulos G, Ardavanis A, Papakotoulas P, Pectasides D, Papadopoulos G, Antoniou D, et al.
Anticancer Drugs
. 2009 Dec;
21(2):202-5.
PMID: 20010424
Oral topotecan has been recently brought into clinical practice at a dose of 2.3 mg/m(2) for 5 days, every 3 weeks. Published data show quite high myelotoxicity. The aim of...
2.
Petraki C, Vaslamatzis M, Petraki K, Revelos K, Alevizopoulos N, Papanastasiou P, et al.
Scand J Urol Nephrol
. 2005 Nov;
39(6):455-63.
PMID: 16303720
Objective: To study the immunophenotypic characteristics and clinical outcome of morphologically undifferentiated prostatic carcinoma with small-cell morphology (U-PC-SCM). Material And Methods: Sixteen patients with U-PC-SCM were enrolled. The streptavidin-biotin complex...
3.
Petraki C, Vaslamatzis M, Argyrakos T, Petraki K, Strataki M, Alexopoulos C, et al.
Int J Surg Pathol
. 2003 May;
11(2):127-35.
PMID: 12754635
Tumor-to-tumor metastases are uncommon. The most frequent donor tumor is lung cancer, while renal cell carcinoma (RCC) is by far the most common recipient. In this report, a carcinoma of...